SLC5A2 and Sepsis: The pooled estimate for sepsis from two studies revealed a significantly lower risk in the SGLT2 inhibitor group than the non-SGLT2 inhibitor group (RR 0.32, 95% CI 0.23–0.44, P < 0.00001) (Fig. 4a).